Trial Profile
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for "Re-examination of New Drugs"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Adverse reactions
- Sponsors AbbVie
- 26 Aug 2020 Status changed from recruiting to completed.
- 30 Dec 2019 Planned number of patients changed from 385 to 415.
- 18 Feb 2019 Planned number of patients changed from 305 to 385.